Large drug firms struggle to compete with generics industry

Cheok Soh Hui; Kovac, Matt
April 2007
ICIS Chemical Business;4/30/2007, Vol. 2 Issue 64, p12
Trade Publication
This article reports on how multinational pharmaceutical companies struggle to find new markets for branded drugs in developing economies. The trend is attributed to consumers in wealthy nations increasingly turning to generic drugs. Brief background on how generic drugs dominate markets in Europe and the U.S. is discussed.


Related Articles

  • The International Pharmaceutical Market as a Source of Low-Cost Prescription Drugs for U.S. Patients. Kesselheim, Aaron S.; Choudhry, Niteesh K. // Annals of Internal Medicine;4/15/2008, Vol. 148 Issue 8, p614 

    In response to increasing prescription drug costs, more U.S. patients and policymakers are importing less-expensive pharmaceutical products from other countries. Large-scale prescription drug importation is currently illegal, but the U.S. Food and Drug Administration permits individuals to bring...

  • Report from: India. Nair, A. // Pharmaceutical Technology;Jul2010, Vol. 34 Issue 7, p18 

    The article focuses on the need for Indian drug companies to monetize their generics to be able to compete in the pharmaceutical industry. The plan to monetize the generics intend to prevent the selling of Indian pharmaceutical firms to multinationals like the megamerger transaction of Piramal...

  • Big pharma sees the light. Boswell, Clay // ICIS Chemical Business;10/12/2009, Vol. 276 Issue 13, p22 

    The article discusses how the faith in generic drugs market is growing among major pharmaceutical companies. Novartis AG has maintained one of the largest generics businesses in the world, Sandoz, since it was formed by the merger of Ciba-Geigy and Sandoz in 1996. In March 2009, Pfizer Inc....

  • High Noon For Hot Markets. Looney, William // Pharmaceutical Executive;Sep2013, Vol. 33 Issue 9, p20 

    The article offers information on the performance of emerging country markets and pharmaceutical industry. It discusses several facts which includes out-of-pocket payment system and no requirement to negotiate access, need of filling gap between high-margin branded generics and middle-class...

  • Gravity Shift: Timely Lessons For Big Pharma. Rehmat, Nadeem // Pharmaceutical Executive;May2014, Vol. 34 Issue 5, p16 

    The article discusses the strategic approaches of generic companies to the emerging pharmaceutical industry in Asia. It refers to the survey by PwC which reveals that Asia could become the biggest pharmaceutical market surpassing the U.S. or Europe. It cites the important lessons pharmaceutical...

  • Strategic Innovation Search by Firms in Weak National Systems of Innovation: The case of the Jordanian Generic Drug Industry. Abuhamad, Abdullah // Jordan Journal of Business Administration;2014, Vol. 10 Issue 1, p145 

    This paper examines why and how some firms embedded in weak National Systems of Innovation out-perform others in their innovation performance. It investigates how strategic practices associated with participation in international collaboration, specifically strategic search, contribute to...

  • Biotechnology in India: Emerging opportunities. Parmar, Himanshu // Journal of Commercial Biotechnology;Oct2005, Vol. 12 Issue 1, p61 

    The global biotechnology and pharmaceutical industry is beleaguered with several challenges such as high R&D costs, increasing regulatory restraints and stagnant product pipelines. Thus, major multinational pharmaceutical and biotechnology companies from the West are increasingly looking for...

  • The Spreading of Licensing Agreements.  // Pharmaceutical Executive;Oct2007, Vol. 27 Issue 10, pS26 

    The article discusses the increasing number of international pharmaceutical companies to use third-party manufacturing and in-licensing agreements in Brazil. Volker Bargon of Boehringer said they were surprised how well it was doing and they have now a good reputation in the generics market....

  • SWOT Analysis.  // PharmaWatch: CNS;Jul2010, Vol. 9 Issue 7, p30 

    The article presents a SWOT analysis on the business operations of global pharmaceutical group Sanovi-Aventis. One of the company's strengths is its position as the leading antithrombotics player in the pharmaceutical industry while the exposition of its key blockbuster is one of its weaknesses....


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics